Accelerating nuclear medicine.

Scroll to explore

Actinium-225 offers new possibilities for high-precision cancer treatments.

Targeting molecules carry actinium-225 to cancer cells by binding to specific markers on their surface. Its powerful, short-range alpha radiation can destroy these cells while limiting damage to surrounding healthy tissue.

Actinium-225 radioligand binding to a cancer-cell receptor A ligand carrying actinium-225 moves into a matching receptor on a cancer cell. A small ring pulses around the payload to suggest radiation. After a pause at binding, the entire cell outline, linker and payload slowly dissolve into small dots that scatter in local bursts. The illustration reforms and repeats; this graphic sequence is not a literal depiction of cell destruction. cancer cell Ac-225

Actinium-225 supply cannot keep pace with growing demand. We are solving this at scale.

Actinium-225 supply with HI-BEAM meeting demand A qualitative illustration: demand rises faster than current supply. Supply becomes supply with HI-BEAM, and the same curve rises to meet and follow demand. The sequence pauses, then repeats. These curves illustrate the intended production scale, not measured values, dates, quantities or a numerical forecast.
Time
Qualitative illustration.

All current supply approaches are limited by the scarcity of their input material or their inability to scale up.

HI-BEAM will produce actinium-225 at industrial scale.

Two proprietary technologies make industrial-scale production possible: a high-power cyclotron optimized for radioisotope production, and a faster, cleaner extraction process.

Supplied HI-BEAM concept rendering, shown in full, including the complete cyclotron and connected beamline.

We use abundant thorium-232, suited for industrial production.

Our starting material is natural thorium-232: abundant and widely available. This removes the dependence on scarce radium-226 or complex nuclear-waste processing.

Supplied laboratory image showing careful handling of material at an analytical balance.

Our team brings together the expertise to develop HI-BEAM.

Transmutex brings together specialists in nuclear physics, accelerator engineering, chemistry, software and industrial development.

Colleagues working together at laboratory equipment.
Colleagues working together at a multi-monitor control-room console.

Management

  • Franklin Servan-Schreiber

    Chief Executive Officer

  • Craig Kelly

    Chief Financial Officer

  • Donovan Maire

    Chief Technical Officer

  • Jean-Christophe de Mestral

    Head of Regulatory and Governmental Affairs

  • Guido Houben

    Managing Director, Transmutex Germany

  • Edouard Servan-Schreiber

    Managing Director, Transmutex USA

  • Michael Daly

    Managing Director, Transmutex Canada

  • Agathe Leclet

    Principal HR Officer

Technical team

  • Alexandre Amorim Carvalho

    Head of Integration Unit

  • Massimo Barbagallo

    Head of Target Unit

  • XiaoXiao Ding

    Head of Quality Assurance

  • Malek Haj Tahar

    Head of Accelerator Unit

  • Karl Johnston

    Head of Extraction Unit

  • Guilhem Lacaze

    Head of Software Unit

  • Monika Sitko

    Head of Planning and Technical Coordination

  • Vasudha Verma

    Head of Nuclear Safety Analyses Unit

Board members

  • Franklin Servan-Schreiber

    Chairman

  • Jean-Christophe de Mestral

    Director

  • Hendrik Höfer

    Director

  • Helen Lin

    Director

  • Victoire Newman

    Director

  • Cameron Porter

    Director

  • Daniel Bertholet

    Observer

  • Brian Steinberg

    Observer

Backed by

Research partners

Your questions about HI-BEAM

How much actinium-225 can HI-BEAM produce?

Up to 200 Curies of actinium-225 per year at full capacity is the design target.

When will Transmutex begin supplying actinium-225?

Initial supply for research and clinical development is targeted for 2028, with full industrial capacity targeted for 2032. We are working with laboratory partners to deliver this.

Has HI-BEAM's technology been validated?

Yes. HI-BEAM builds on mature accelerator and target technologies and a demonstrated thorium irradiation and purification pathway. Our proprietary technology brings these components together for industrial production.

Can HI-BEAM produce other radioisotopes?

HI-BEAM is currently optimized for actinium-225, but its targets are engineered to produce other radioisotopes simultaneously, including lead-212, radium-223 and strontium-82.

Contact

Discuss isotope supply, partnerships, investment or career.

Contact the team